Sirna Therapeutics to Present at 2006 BIO InvestorForum
11 Octubre 2006 - 9:00AM
PR Newswire (US)
SAN FRANCISCO, Oct. 11 /PRNewswire-FirstCall/ -- Sirna
Therapeutics, Inc. ("Sirna") (NASDAQ:RNAI), a leading RNAi
therapeutics company, announced today that senior management will
give a company presentation at the 2006 Biotechnology Industry
Organization InvestorForum on Wednesday, October 18, 2006 at 11:00
a.m. PT at the Palace Hotel in San Francisco, CA. For more
information on this conference, please log onto:
http://investorforum.bio.org/opencms/bif/2006/index.jsp About Sirna
Therapeutics Sirna Therapeutics is a clinical-stage biotechnology
company developing RNAi-based therapies for serious diseases and
conditions, including age-related macular degeneration (AMD),
hepatitis C, dermatology, asthma, respiratory syncytial virus (RSV)
and Huntington's disease. Sirna Therapeutics completed its Phase 1
clinical trial for Sirna-027 in AMD in 2005 and with its strategic
partner, Allergan, Inc., is moving Sirna-027 forward into Phase 2
clinical trials. Sirna has selected a clinical candidate for
hepatitis C virus, Sirna-034, which the Company plans to bring into
Phase 1 clinical trials by the end of 2006. Sirna has established
an exclusive multi-year strategic alliance with GlaxoSmithKline for
the development of siRNA compounds for the treatment of respiratory
diseases. Sirna has a leading intellectual property portfolio in
RNAi covering over 250 mammalian gene and viral targets and over
200 issued or pending patents covering other major aspects of RNAi
technology, including the microRNA technology. More information on
Sirna Therapeutics is available on the Company's web site at
http://www.sirna.com/. Safe Harbor Statement Statements in this
press release which are not strictly historical are
"forward-looking" statements which should be considered as subject
to many risks and uncertainties. For example, most drug candidates
do not become approved drugs. The development of Sirna-027 and
Sirna-034 as well as Sirna's other programs are still at a
relatively early stage. All of these programs, and Sirna's ability
to obtain milestone and royalty payments for them, are subject to
significant risks and unknowns, are highly contingent upon future
successes, and require significant funding. In addition, patent
applications may not result in issued patents, and issued patents
may not be enforceable or could be invalidated. Other risks and
uncertainties include, among others, Sirna's early stage of
development, Sirna's history and expectation of losses and need to
raise capital, Sirna's need to obtain clinical validation and
regulatory approval for Sirna-027, Sirna-034 and Sirna's other
product candidates, any of which could have negative results,
Sirna's need to engage collaborators, Sirna's need to obtain and
protect intellectual property, and the risk of third-party patent
infringement claims. These and additional risk factors are
identified in Sirna's Securities and Exchange Commission filings,
including Forms 10-K and 10-Q and in other SEC filings. Sirna
undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may
arise after the date of this release. Contacts: Stephan Herrera
Executive Director, Investor Relations Sirna Therapeutics, Inc. +1
415 512 7200 Stephanie Carrington The Ruth Group +1 646 536 7017
DATASOURCE: Sirna Therapeutics, Inc. CONTACT: Stephan Herrera,
Executive Director, Investor Relations of Sirna Therapeutics, Inc.,
+1-415-512-7200, ; or Stephanie Carrington of The Ruth Group,
+1-646-536-7017, , for Sirna Therapeutics, Inc. Web site:
http://investorforum.bio.org/opencms/bif/2006/index.jsp Web site:
http://www.sirna.com/
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sirna Therapeutics (NASDAQ:RNAI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024